Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A imaging study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis (IBM)

Next Previous
X
Search
Trial Profile

A imaging study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis (IBM)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crefmirlimab (Primary)
  • Indications Inclusion body myositis
  • Focus Diagnostic use

    • Most Recent Events

    • 08 Jul 2021 New trial record
    • 30 Jun 2021 According to an Abcuro media release, company and ImaginAb shared initial results of this study.
    • 30 Jun 2021 According to an Abcuro media release, this studywas led by Colin Quinn, M.D., Assistant Professor of Clinical Neurology and Director of Neuromuscular Clinical Trials at the University of Pennsylvania.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top